ZTS Stock Price Today (July 2026) — Zoetis Inc. Analysis & Key Metrics 2026-07-17
Zoetis Inc. (ZTS) is trading at $76.56, down 0.46% today (as of July 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $124.00 (62.0% upside).
- Volatility remains elevated (25.10% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.90% YoY) alongside significant competitive pressures.
ZTS Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Zoetis Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $37.44B
P/E Ratio
Forward P/E: 9.72
Revenue Growth
Year over Year
Analyst Target
+62.0% upside potential
Key Investor Questions About ZTS
What investors need to know before buying
Based on current market data, ZTS presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 52.37)
- Fundamentals say: Caution warranted (high leverage concerns)
ZTS's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ZTS investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $9.25B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, ZTS stock traded between $71.47 and $161.77—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 25.10% annualized volatility and β=0.64, the stock exhibits low sensitivity to market moves—making ZTS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Zoetis Earnings Preview: What to Expect
Zoetis is set to post its second-quarter results next month, and analysts project a single-digit earnings rise.
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
Zoetis (ZTS) closed at $74.07 in the latest trading session, marking a -1.75% move from the prior day.
A Dividend Portfolio That Pays For Your Pets
Rescuing a dog or cat can easily turn into a 10- to 20-year financial commitment. Medium-sized dogs often live around 10 to 13 years, while many cats live into their mid-teens and some stretch past 18. The bill that comes with that lifespan is the part many owners never total, because the monthly receipts feel ... A Dividend Portfolio That Pays For Your Pets
2 Value Stocks with Promising Prospects and 1 That Underwhelm
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
ZTS Wins European Commission Approval for New Poultry Disease Vaccine
Zoetis wins EU approval for a single-dose poultry vaccine against Newcastle and Marek's diseases, expanding its vaccine portfolio and flock protection options.
Deadly Screwworm’s Leap Into the US Mystifies Health Experts
(Bloomberg) -- As the deadly New World screwworm spreads through Texas, posing significant risk to the US cattle herd, experts are still puzzling over the mystery of how it got there.Most Read from BloombergGreece Offers Bounty to Catch Ravenous Fish Lured by Warming SeaOil, Gas Tankers Cross Hormuz Via Oman-Side Route After U-TurnsThe Tanker Tycoon Making Millions on Hormuz Shuttle RunsModi’s Flagship Biofuel Push Faces Backlash From MotoristsOil’s Supply Wave, Tumbling Prices Rekindle Fears of
Michael Burry Just ‘Shorted Micron’ — Why He Says AI-Fueled Rally Has Pushed MU Into Bubble Territory
The ‘Big Short’ investor says Micron’s valuation, technical setup and cyclical history point to significant downside after its AI-driven rally.
Branded Pharmaceuticals Stocks Q1 Teardown: Zoetis (NYSE:ZTS) Vs The Rest
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Zoetis (NYSE:ZTS) and its peers.
Zoetis (ZTS) Index Shift: A Harbinger for Its Competitive Moat in Companion-Animal Health?
On June 27, 2026, Zoetis Inc. was removed from several Russell Top 200 indexes and simultaneously added to the Russell Midcap Index and its value and growth benchmarks, reflecting a shift in how the company is classified within major equity indices. This index reclassification comes amid weaker demand for key osteoarthritis treatments, intensifying competition, and pending securities class actions that have focused attention on Zoetis’s risk profile and business momentum. Against this...
This Analyst Thinks Stabilization For Zoetis’ Products ‘Could Be Several Quarters Away’
Barclays’ latest commentary on Zoetis comes in the aftermath of Zoetis’ first-quarter earnings, which it described as “challenging.”
Frequently Asked Questions
Common investor questions about Zoetis Inc.
Zoetis Inc. (ZTS) is currently trading at $76.56. The RSI (14-day) is at 52.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $124.00 implies 62.0% upside from current levels. Volatility is moderate at 25.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Zoetis Inc. (ZTS): The trailing P/E ratio is 12.55, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 9.72, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.72, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 9.77. Price-to-Sales is 3.37. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 17 analysts covering ZTS, the consensus price target is $124.00. This represents a 62.0% upside from the current price of $76.56. The range spans from a low target of $85.00 to a high target of $160.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Zoetis Inc. (ZTS) pays a dividend with a current yield of approximately 2.77%. The annualized dividend rate is $2.03 per share. The payout ratio is 33.3%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-07-20T00:00:00.000Z.
Key risks for Zoetis Inc. (ZTS) investors include: 1. Moderate volatility (25.1% annualized)—price swings are notable. 2. Elevated debt levels (D/E ratio of 286.24) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Zoetis Inc.'s (ZTS) current debt and financial health profile: Total debt stands at $9.25B. The debt-to-equity ratio is 286.24, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 3.15, indicating strong short-term liquidity. The quick ratio is 1.68. The company holds $1.94B in cash and equivalents. Free cash flow is positive at $1.78B, providing a cushion for debt servicing and shareholder returns.